Adam's Take - Page 3 of 5

Adam's Take

Celgene is perking up. Here’s what needs to happen for the momentum to continue

By Adam Feuerstein

Adam's Take

Red flags fly over Anavex: What’s stopping the drug maker from enrolling U.S., European patients in trials?

By Adam Feuerstein

Adam's Take

ALS drug maker walks back plan to profit from right-to-try law following heavy criticism

By Adam Feuerstein

Adam's Take

Here come the right-to-try profiteers. The FDA is powerless to stop them

By Adam Feuerstein

Adam's Take

Geron wants J&J to continue a drug development partnership, but new data weaken its case

By Adam Feuerstein

Adam's Take

Questionable data aside, Galmed Pharma soars in a fatty liver stock bubble

By Adam Feuerstein

Adam's Take

Proteostasis cystic fibrosis drug disappoints, easing competitor concerns for Vertex Pharma

By Adam Feuerstein

Adam's Take

Omeros is bullish on its plan for speedy approval of a rare disease drug. Its plan has flaws

By Adam Feuerstein

Adam's Take

A deeply troubled drug company fires its CEO, who then unfires himself. Comedy, chaos ensue

By Adam Feuerstein

Adam's Take

After watching Trump’s drug speech, investors poured big money into biotech funds

By Adam Feuerstein

Adam's Take

Biotech stocks open higher Monday on ‘Trump bump’

By Adam Feuerstein

Adam's Take

Biotech updates: Amicus, Aveo Oncology, Akcea Therapeutics, and Ionis Pharma

By Adam Feuerstein

Adam's Take

A strong Celgene earnings report gives investors reasons to start trusting again

By Adam Feuerstein

Adam's Take

Gilead’s ‘trough year’ looking harder to dig out from after miserable first quarter

By Adam Feuerstein

Adam's Take

Celgene’s beaten-down stock is cheap, but only if investors regain trust in its financial outlook

By Adam Feuerstein

Adam's Take

This biotech CEO’s lousy job performance cost shareholders money, so his board docked his pay

By Adam Feuerstein

Adam's Take

SEC extends probe into Northwest Biotherapeutics as financial struggles mount

By Adam Feuerstein

Adam's Take

Biogen and the badly needed gene therapy acquisition that got away

By Adam Feuerstein

Adam's Take

Experimental drug might reduce fat in blood, but a NASH cure? Not so fast

By Adam Feuerstein

Adam's Take

Biotech saw positive results this quarter; shares still tanked. Here are some explanations

By Adam Feuerstein

Adam's Take

The top-performing biotech stock this year has surged on flimsy data

By Adam Feuerstein

Adam's Take

AnaptysBio peanut allergy shot improves tolerance, aided by generous reading of data

By Adam Feuerstein

Adam's Take

Biotech CEOs talk a lot. Here’s how to spot the red flags in what they’re saying

By Adam Feuerstein

Adam's Take

Martin Shkreli has been sentenced. The drug industry is trying to get away scot-free

By Adam Feuerstein

Adam's Take

Marinus Pharma finds the biotech imitation game can only last so long

By Adam Feuerstein

Adam’s Take

Gilead Sciences’ board is looking for a new CEO. Here’s a list of possible contenders

Gilead’s golden era ends with the executive departures of ‘The Johns’

ResTORbio drug study results weaken under scrutiny

Preclinical biotech companies are having an IPO bonanza. What’s the draw for investors?

Celgene is perking up. Here’s what needs to happen for the momentum to continue

Red flags fly over Anavex: What’s stopping the drug maker from enrolling U.S., European patients in trials?

ALS drug maker walks back plan to profit from right-to-try law following heavy criticism

Here come the right-to-try profiteers. The FDA is powerless to stop them

Geron wants J&J to continue a drug development partnership, but new data weaken its case

Questionable data aside, Galmed Pharma soars in a fatty liver stock bubble

Proteostasis cystic fibrosis drug disappoints, easing competitor concerns for Vertex Pharma

Omeros is bullish on its plan for speedy approval of a rare disease drug. Its plan has flaws

A deeply troubled drug company fires its CEO, who then unfires himself. Comedy, chaos ensue

After watching Trump’s drug speech, investors poured big money into biotech funds

Biotech stocks open higher Monday on ‘Trump bump’

Biotech updates: Amicus, Aveo Oncology, Akcea Therapeutics, and Ionis Pharma

A strong Celgene earnings report gives investors reasons to start trusting again

Gilead’s ‘trough year’ looking harder to dig out from after miserable first quarter

Celgene’s beaten-down stock is cheap, but only if investors regain trust in its financial outlook

This biotech CEO’s lousy job performance cost shareholders money, so his board docked his pay

SEC extends probe into Northwest Biotherapeutics as financial struggles mount

Biogen and the badly needed gene therapy acquisition that got away

Experimental drug might reduce fat in blood, but a NASH cure? Not so fast

Biotech saw positive results this quarter; shares still tanked. Here are some explanations

The top-performing biotech stock this year has surged on flimsy data

AnaptysBio peanut allergy shot improves tolerance, aided by generous reading of data

Biotech CEOs talk a lot. Here’s how to spot the red flags in what they’re saying

Martin Shkreli has been sentenced. The drug industry is trying to get away scot-free

Marinus Pharma finds the biotech imitation game can only last so long